Neuroscientific Biopharmaceuticals (ASX:NSB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Neuroscientific Biopharmaceuticals (ASX:NSB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Results of Annual General Meeting
US FDA Provides Positive Feedback on Planned Phase 2 Trial
FDA supports NSB's planned Phase 2 StemSmart Crohn's disease trial
Leading CRO Appointed for Phase 2 Crohn's Trial
NeuroScientific appoints Southern Star Research for Phase 2 Crohn's disease trial
Notice of Annual General Meeting & Proxy Form
Letter to Shareholders & Proxy Form
Resignation and Appointment of Auditor
Appendix 4G & Corporate Governance Statement
2026 Annual Report & Appendix 4E
NeuroScientific reports $4.69M loss, advances StemSmart clinical program, ceases EmtinB development
Pre-IND Meeting with US FDA Scheduled
NSB schedules Pre-IND meeting with US FDA for Phase 2 trial of StemSmart in refractory Crohn's disease
Quarterly Activities/Appendix 4C Cash Flow Report
NeuroScientific reports positive clinical results for StemSmart™ in Crohn's disease and advances Phase 2 trial planning
